Want to see ORGO full AI Analyst Report?
ORGO Stock Chart & Stats
$4.08
-$0.06(-1.89%)
At close: 4:00 PM EST
$4.08
-$0.06(-1.89%)
Day’s Range― - ―
52-Week Range$2.04 - $7.08
Previous CloseN/A
Volume97.61K
Average Volume (3M)826.12K
Market Cap
$316.54M
Enterprise Value$279.86M
Total Cash (Recent Filing)$92.10M
Total Debt (Recent Filing)$70.86M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding128,674,550
10 Day Avg. Volume760,428
30 Day Avg. Volume826,115
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.17
P/FCF Ratio-26.84
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue0.54
Enterprise Value/Gross Profit0.77
Enterprise Value/Ebitda7.50
Forecast
1Y Price Target
$3.00Price Target Upside-26.47% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.82
Revenue Forecast (FY)$282.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~69% gross margins reflect durable product-level economics for biologic/tissue offerings. Strong gross margins provide a cushion to absorb demand shocks, support cash generation and R&D spend, and increase the chance of returning to operating profitability as volumes recover.
BLA Submission For ReNuA completed BLA for ReNu is a structural growth milestone that could materially expand addressable market into nonsurgical knee OA. Regulatory approval would diversify revenue beyond wound care, create a new durable commercial channel and justify continued clinical and commercialization investments.
Solid Liquidity And Low LeverageA strong liquidity position with no outstanding debt and revolver capacity gives management runway to fund clinical programs, restructuring and commercialization initiatives. Balance-sheet flexibility lowers refinancing risk and supports execution through policy-driven demand volatility.
Bears Say
Sharp Revenue Decline And Downgraded GuidanceA multiyear-scale decline in revenue and a materially reduced full-year outlook signal a meaningful loss of utilization and scale. Reduced revenue compresses fixed-cost absorption, strains operating leverage, limits reinvestment capacity and prolongs the timeline to normalized profitability and growth.
Profitability Volatility And Inventory ChargesLarge inventory write-downs and regulatory charges reveal forecasting and execution risks tied to product demand and compliance. These episodic losses demonstrate operating volatility, undermine margin sustainability and increase the likelihood of future one-time impairments if utilization remains depressed.
CMS Disruption And Claims-processing HeadwindsReimbursement policy uncertainty and third-party processing problems create durable demand risk for wound-care products, as clinician use and billing are sensitive to coverage clarity. Recovery depends on external clarifications, making revenue and utilization improvements uncertain and operationally exposed.
Organogenesis Holdings News
ORGO FAQ
What was Organogenesis Holdings’s price range in the past 12 months?
Organogenesis Holdings lowest stock price was $2.04 and its highest was $7.08 in the past 12 months.
What is Organogenesis Holdings’s market cap?
Organogenesis Holdings’s market cap is $316.54M.
When is Organogenesis Holdings’s upcoming earnings report date?
Organogenesis Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Organogenesis Holdings’s earnings last quarter?
Organogenesis Holdings released its earnings results on May 07, 2026. The company reported -$0.366 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.076.
Is Organogenesis Holdings overvalued?
According to Wall Street analysts Organogenesis Holdings’s price is currently Overvalued.
Does Organogenesis Holdings pay dividends?
Organogenesis Holdings does not currently pay dividends.
What is Organogenesis Holdings’s EPS estimate?
Organogenesis Holdings’s EPS estimate is -0.35.
How many shares outstanding does Organogenesis Holdings have?
Organogenesis Holdings has 128,674,550 shares outstanding.
What happened to Organogenesis Holdings’s price movement after its last earnings report?
Organogenesis Holdings reported an EPS of -$0.366 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -6.324%.
Which hedge fund is a major shareholder of Organogenesis Holdings?
Currently, no hedge funds are holding shares in ORGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organogenesis Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (-26.47% Downside)
$3.00 (-26.47% Downside)
Blogger Sentiment
Bullish
ORGO Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 18.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.84%
12-Months-Change
Fundamentals
Return on Equity
-0.07%
Trailing 12-Months
Asset Growth
11.25%
Trailing 12-Months
Company Description
Organogenesis Holdings
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
ORGO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call detailed significant near-term financial deterioration driven by market disruption and policy-related clinician confusion: Q1 revenue fell 58% YoY, margins compressed sharply, and losses widened, prompting a material downgrade to full-year revenue guidance and a March restructuring. Offsetting these negatives are important strategic and clinical milestones — completion of a BLA submission for ReNu, a positive 170‑patient RCT for PuraPly AM, evidence of relative market share gains, disciplined cost reductions, and a solid cash position with no debt. While these highlights support longer-term confidence, they do not fully mitigate the severe short-term revenue and profitability declines and the uncertainty around CMS policy timing.View all ORGO earnings summariesORGO Stock 12 Month Forecast
Average Price Target
$3.00
▼(-26.47% Downside)
Technical Analysis
Ownership Overview
17.00% Insiders
7.01% Mutual Funds
1.69% Other Institutional Investors
62.12% Public Companies and
Individual Investors